Cyteir lays off 70% of workforce after further narrowing cancer drug goals

Cyteir lays off 70% of workforce after further narrowing cancer drug goals

Source: 
Fierce Biotech
snippet: 

Back in the summer, Cyteir Therapeutics announced that it was pressing pause on plans to get one of its cancer meds into the clinic. But it’s only now that we’re seeing the fallout of the decision to focus on its lead ovarian cancer asset—in the form of laying off 70% of its workforce.